Entrada Therapeutics, Inc.
TRDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001689375
In the last 90 days, Entrada Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 128 institutions reported holding it in 13F filings for Q2 2026, worth $214.4M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Entrada Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 46 | 48 | +2 |
| Shares | 25.4M | 25.9M | +506.3K (+2.0%) |
| Value | $433.8M | $242.8M | −$191.0M (−44.0%) |
New holders (8)
Institutions that held Entrada Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nan Fung Group Holdings Ltd | 173,582 | $1.63M | 0.77% |
| Walleye Capital LLC | 44,652 | $419.0K | 0.01% |
| Manufacturers Life Insurance Company, The | 41,175 | $393.1K | 0.00% |
| New York State Common Retirement Fund | 4,880 | $46.0K | 0.00% |
| Barclays PLC | 1,709 | $16.0K | 0.00% |
| Amalgamated Bank | 1,350 | $13.0K | 0.00% |
| Amalgamated Financial Corp. | 1,350 | $13.0K | 0.00% |
| Nisa Investment Advisors, LLC | 700 | $7.00K | 0.00% |
Sold out (6)
Institutions that held Entrada Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Avidity Partners Management LP | 255,000 | $4.37M |
| Millennium Management LLC | 46,504 | $796.0K |
| Cubist Systematic Strategies, LLC | 11,090 | $190.0K |
| Caas Capital Management LP | 10,000 | $171.0K |
| Advisor Group Holdings, Inc. | 300 | $5.00K |
| Point72 Hong Kong Ltd | 215 | $4.00K |